Wockhardt Share Price Gains for the 2nd Straight Day as USFDA Accepts NDA for Antibiotic Zaynich

Shares of Wockhardt saw a sharp rise on 2 December 2025 after the US Food and Drug Administration (USFDA) accepted the New Drug Application (NDA) for the company’s antibiotic Zaynich. 

The stock outperformed broader market indices despite early trade declines, reflecting investor interest in the regulatory milestone and technical momentum.

USFDA Acceptance Boosts Investor Sentiment

The USFDA acceptance of the NDA for Zaynich has been viewed positively by the market. This regulatory development positions Wockhardt for potential product launches in the US, providing long-term revenue opportunities.

Investors reacted quickly, driving the stock higher during the early session on both the BSE and NSE.

Wockhardt Share Price Performance

Wockhardt’s shares were trading at ₹1,521.70 as of 11:03 AM, marking a gain of 3.36% from the previous close of ₹1,472.20. The stock opened at ₹1,492, touched an intraday high of ₹1,566.90, and a low of ₹1,465.70.

Read More: Government Urges Hospitals and Insurers to Work Together to Reduce Health Insurance Costs.

Conclusion

Wockhardt’s share price movement underscores the market’s positive reaction to the USFDA’s NDA acceptance for Zaynich. While regulatory approval enhances potential revenue prospects, investors are likely to monitor the company’s commercial execution and broader market conditions.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.